FontNL schreef op 25 juli 2018 14:46:
Kom gooi ik er ff een inhoudelijk berichtje tussen door,
July 25, 2018
Analysts See $-0.91 EPS for Galapagos NV (GLPG); Hillhouse Capital Management LTD Has Decreased By $558.97 Million Its Jd Com (JD) Position
Analysts expect Galapagos NV (NASDAQ:GLPG) to report $-0.91 EPS on July, 30.They anticipate $0.10 EPS change or 12.35% from last quarter’s $-0.81 EPS. After having $-0.90 EPS previously, Galapagos NV’s analysts see 1.11% EPS growth. The stock increased 0.59% or $0.63 during the last trading session, reaching $108.21. About 78,054 shares traded. Galapagos NV (NASDAQ:GLPG) has risen 20.58% since July 25, 2017 and is uptrending. It has outperformed by 8.01% the S&P500. Some Historical GLPG News: 24/04/2018 – Galapagos reports initiation of FALCON clinical trial in cystic fibrosis; 12/04/2018 – GALAPAGOS NV – GLOBAL PHASE 3 PROGRAM IS EXPECTED TO CONSIST OF TWO IDENTICALLY DESIGNED TRIALS, ISABELA 1 AND ISABELA 2; 30/05/2018 – GALAPAGOS NV – IN TRIAL ONE OTHER PATIENT RECEIVING FILGOTINIB DEVELOPED HERPES ZOSTER; 11/03/2018 – 5.2 MAG. EARTHQUAKE GALAPAGOS ISLANDS ECUADOR :EMSC; 19/04/2018 – Good news for $GLPG $GILD $ABBV is that FDA sees thrombosis as a unique issue with $INCY $LLY baricitinib and not seen with other JAKi; 01/05/2018 – Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients; 23/05/2018 – Galapagos Holding S.A.: NOTIFICATION TO BONDHOLDERS; 25/04/2018 – GALAPAGOS NV GLPG.AS – QTRLY NET LOSS OF EUR 37.3 MLN; 25/04/2018 – GALAPAGOS NV GLPG.AS – AIMS TO REPORT TOPLINE RESULTS WITH TORTUGA (ANKYLOSING SPONDILITIS) FILGOTINIB STUDY; 20/05/2018 – REG-GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS